期刊
ANNALS OF HEMATOLOGY
卷 95, 期 5, 页码 707-718出版社
SPRINGER
DOI: 10.1007/s00277-016-2621-2
关键词
MPN; Myeloproliferative neoplasms; Bleeding; Hemorrhage; Management; Essential thrombocythemia; Polycythemia vera; Review
类别
资金
- Bristol Myers Squibb
- Novartis
- Sanofi
- Merck
- Baxter
- Bayer
- Biotest
- Boehringer Ingelheim
- CSL Behring
- Leo Pharma
- Novo Nordisk
- Octapharma
- Pfizer
- Amgen
- Aspen Germany
- Behring
- Bristol-Myers Squibb
- GlaxoSmithKline
- Roche
- Novartis Foundation
- Ariad
- Alexion
- AOP
- Baxalta
- Celgene
- CTI
- Shire
Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN) comprise a heterogeneous group of chronic hematologic malignancies. The quality of life, morbidity, and mortality of patients with MPN are primarily affected by disease-related symptoms, thromboembolic and hemorrhagic complications, and progression to myelofibrosis and acute leukemia. Major bleeding represents a common and important complication in MPN, and the incidence of such bleeding events will become even more relevant in the future due to the increasing disease prevalence and survival of MPN patients. This review discusses the causes, differential diagnoses, prevention, and management of bleeding episodes in patients with MPN, aiming at defining updated standards of care in these often challenging situations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据